GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

Key facts

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Principal Investigator

Zhenfeng Zhang, MD,PhD

Second Affiliated Hospital of Guangzhou Medical University

Intervention

GPC3 and/or TGFβ targeting CAR-T cells(biological)

Enrollment

30 enrolled

Eligibility

18-75 years · All sexes

Timeline

2017 – 2036

Study locations (2)

• The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
• The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Collaborators

Hunan Zhaotai Yongren Medical Innovation Co. Ltd. · Guangdong Zhaotai InVivo Biomedicine Co. Ltd. · First Affiliated Hospital, Sun Yat-Sen University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cancer-associated retinopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT05038696
  ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
  National University Hospital, Singapore

See all trials for Cancer-associated retinopathy →